Cultivate at Scale, a facility designed to support the scaling of cellular agriculture, has entered into a collaboration with ...

After a long winter, the start of summer is ushering in some much-needed sunshine, warmer weather and, for a handful of ...

Zenas BioPharma has released its corporate presentation for June 2025, providing an insight into its financial and clinical ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

XP 8121 is a combination drug meant to better control hypothyroidism, in part by moving its common therapy, levothyroxine, ...

Unpredictable and politically driven regulatory approaches cultivate an environment of enormous uncertainty for vaccine ...

The Drug Enforcement Administration is under growing scrutiny for alleged ethical violations, constitutional defiance, and ...

McKesson Corp. has announced plans to separate its Medical-Surgical Solutions segment into an independent company. This strategic move is aimed at sharpening McKesson’s focus on higher-growth, higher- ...